Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines

M. Lambertini¹², F. A. Peccatori¹, I. Demeestere⁴, F. Amant¹⁶, C. Wyns⁷, J.-B. Stukenborg⁸, S. Paluch-Shimon⁶, M. J. Halaska¹⁰, C. Uzan¹¹, J. Meissner¹², M. von Wolff¹³, R. A. Anderson¹⁴ & K. Jordan¹², on behalf of the ESMO Guidelines Committee*

¹Department of Internal Medicine and Medical Specialties (DiMi), School of Medicine, University of Genoa, Genoa; ²Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Poli clinico San Martino, Genoa; ³Fertility and Procreation Unit, Division of Gynecologic Oncology, European Institute of Oncology IRCCS, Milan, Italy; ⁴Research Laboratory on Human Reproduction, Fertility Clinic, CUB-Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium; ⁵Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute/Antoni van Leeuwenhoek and Amsterdam University Medical Centers, Amsterdam, The Netherlands; ⁶Department of Oncology, KU Leuven, Leuven; ⁷Department of Gynecology and Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; ⁸NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; ⁹Division of Oncology, Sharrett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel; ¹⁰Department of OB/GYN, ³rd Medical Faculty, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic; ¹¹Department of Breast and Gynecologic Surgery, APHP, Hospital Pitié Salpêtrière, Sorbonne Université, Paris, France; ¹²Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Germany; ¹³University Women’s Hospital, Division of Gynecological Endocrinology and Reproductive Medicine, Bern, Switzerland; ¹⁴MRC Centre for Reproductive Health, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

Available online 22 September 2020

Key words: cancer, Clinical Practice Guidelines, fertility, pregnancy

INTRODUCTION

Cancer remains a public health problem worldwide that also includes young adults.¹ Given the ongoing improvements in survival for most malignancies, a significant proportion of people affected by cancer face the consequences of treatment-related late effects, making survivorship an area of crucial importance.²

At the time of diagnosis, a significant proportion of young patients are concerned about the possible impact of anticancer treatments on their fertility and future chances of conception.³,⁴ Failure to address these concerns may negatively influence their choices and adherence to the proposed anticancer treatments. Considering the rising trend in delaying childbearing and the higher number of patients who have not completed their family planning at the time of diagnosis, the demand for fertility preservation and information about the feasibility and safety of pregnancy following treatment completion is expected to increase.

These guidelines provide a framework for fertility preservation and post-treatment pregnancies in post-pubertal cancer patients and include new topics beyond the previous European Society for Medical Oncology (ESMO) recommendations published in 2013.⁵ The specific issues faced by prepubertal patients, indications for fertility-sparing surgery and management of cancer diagnosed during pregnancy are beyond the scope of these guidelines.

ASSESSMENT OF GONADOTOXICITY

Oncofertility counselling

All cancer patients of reproductive age should receive complete oncofertility counselling as early as possible in the treatment planning process, irrespective of type and stage of disease. This should include discussion of the patients’ current or future family desire, their health and prognosis, the potential impact of the disease and/or proposed anticancer treatment on their fertility and gonadal function, chances of future conception, pregnancy outcomes and offspring, as well as the need for effective contraception in the context of systemic anticancer treatment.⁶ To ensure that patients fully understand the risk of treatment-related gonadotoxicity, they should be offered complete oncofertility counselling even if there is no interest in future children at the time of diagnosis.

Oncofertility counselling should be individualised based on patient/couple- and disease/treatment-related factors, with patient interest and age as well as type of treatment being the most important (Table 1). Written information and/or online resources should be provided to all patients, whenever possible, and should be documented in the
Gonadotoxicity of anticancer treatments

Both the proposed anticancer therapies, as well as the type of cancer and the overall condition of the patient may induce treatment-related gonadal failure and infertility (defined as an impairment of a person’s capacity to reproduce).9

The risk of treatment-related azoospermia or amenorrhea according to different anticancer treatments is summarised in Tables 2 and 3, respectively (updated from Lee et al.10).

Male patients. Male causes of infertility encompass abnormal semen parameters; anatomical, endocrine, genetic, functional or immunological abnormalities of the reproductive system; chronic illness and sexual conditions incompatible with the ability to deposit semen in the vagina.11

Spermatogonia are the most important target of cytotoxic treatments. The damaging effect depends on the drug concentration or the radiotherapy (RT) dose.12 Suppression of gonadotropin release following cranial RT may also impact on spermatogenesis, although this may be corrected by exogenous gonadotropin administration.

While low doses of chemotherapy (ChT) reduce the pool of actively dividing spermatogonia, reserve spermatogonial stem cells might survive and remain able to differentiate. Treatment-related gonadotoxicity can also be caused indirectly by a depletion and impairment of Sertoli and Leydig cells.12 The most severe damage to spermatogonia and germinal epithelium is induced by alkylating agents, platinum compounds and long-term hydroxyurea treatment.10,13

<table>
<thead>
<tr>
<th>Patient/couple-related factors</th>
<th>Disease/treatment-related factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Type of cancer (prognosis and risk of gonad involvement by the tumour)</td>
</tr>
<tr>
<td>Age</td>
<td>Urgency of treatment</td>
</tr>
<tr>
<td>BMI</td>
<td>Type of treatment:</td>
</tr>
<tr>
<td>Smoking</td>
<td>ChT:</td>
</tr>
<tr>
<td>Presence of a partner</td>
<td>◦ Regimen</td>
</tr>
<tr>
<td>Medical history</td>
<td>◦ Dose</td>
</tr>
<tr>
<td>Ovarian reserve markers (female)</td>
<td>◦ Location of the RT field</td>
</tr>
<tr>
<td>Previous treatment for infertility</td>
<td>◦ Dose and fractionation</td>
</tr>
<tr>
<td>Prior treatment with potential negative impact on fertility</td>
<td>Endocrine therapy</td>
</tr>
<tr>
<td>or surgical fertility preservation options</td>
<td>Surgery</td>
</tr>
<tr>
<td>Hereditary conditions</td>
<td>Duration of treatment</td>
</tr>
</tbody>
</table>

BMI, body mass index; ChT, chemotherapy; RT, radiotherapy.

<table>
<thead>
<tr>
<th>Degree of risk</th>
<th>Treatment type/regimen</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk</td>
<td>Total body RT</td>
<td></td>
</tr>
<tr>
<td>Testicular RT</td>
<td>germ cells &gt; 20 Gy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>somatic cells &gt; 30 Gy</td>
<td></td>
</tr>
<tr>
<td>ChT</td>
<td>Alkylating agents</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(cyclophosphamide,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ifosfamide, procarbazine,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cisplatin, chlorambucil,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carmustine, lomustine,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>melphalan, thiopeta, busulfan, mechloretheramine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>with CED &gt; 5 g/m² for germ cells and 20 g/m² for somatic cells</td>
<td></td>
</tr>
<tr>
<td>Conditioning ChT for BMT</td>
<td>(busulfan and cyclophosphamide, fludarabine and melphalan)</td>
<td></td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>Alkylating agents (thiopeta, cisplatin &lt; 0.6 g/m², oxaliplatin, carboplatin, dacarabazine)</td>
<td></td>
</tr>
<tr>
<td>Anthracyclines</td>
<td>(doxorubicin, idarubicin, daunorubicin)</td>
<td></td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td>Antimetabolites (cytarabine, gencitabine)</td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>Antimetabolites</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(mercaptopurine, methotexate, fludarabine)</td>
<td></td>
</tr>
<tr>
<td>Tubulin-binding agents/vinca alkaloids</td>
<td>(vincristine, vinblastine)</td>
<td></td>
</tr>
<tr>
<td>Topoisomerase inhibitors (etoposide)</td>
<td>Antitumour antibiotics (bleomycin, dactinomycin, mitomycin C)</td>
<td></td>
</tr>
<tr>
<td>Unknown risk</td>
<td>Antimetabolites</td>
<td>For taxanes, only very short-term evaluation (&lt;6 months); increased FSH, decreased inhibin B and testicular volume when measured just after completion of combined ChT</td>
</tr>
<tr>
<td></td>
<td>Antimetabolites</td>
<td>Limited evidence for imatinib</td>
</tr>
<tr>
<td></td>
<td>(fluorouracil, thiohuargine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Taxanes (paclitaxel, docetaxel)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topoisomerase inhibitors (irinotecan, topotecan, teniposide)</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>Targeted therapies (including monoclonal antibodies and small molecules)</td>
<td></td>
</tr>
</tbody>
</table>

BMT, bone marrow transplantation; CED, cyclophosphamide equivalent dose; ChT, chemotherapy; FSH, follicle-stimulating hormone; RT, radiotherapy.

Adapted from Lee et al.12 Table contains examples and is not a complete list.

Table 2. Risks of treatment-related azoospermia and infertility in male patients

Table 1. Patient/couple- and disease/treatment-related factors to be considered during oncofertility counselling at the time of diagnosis
The germinall epithelium is highly susceptible to RT-related damage. Spermatogonial stem cells and stem cells of the testis are also highly susceptible, with doses as low as 0.1 Gy leading to clinical testicular failure. Doses of 2-3 Gy also affect spermatogonial stem cells and cause long-term azaosperma. Doses of >6 Gy (e.g. total body RT with 10 or 13 Gy) deplete the spermatogonial stem cell pool and cause long-term or permanent infertility. Leydig cell insufficiency and testosterone deficiency have been described with RT doses of >20-24 Gy. A potential negative impact of cancer on semen parameters has been described for patients with testicular tumours and Hodgkin’s lymphoma.

Female patients. Cancer and anticancer treatments may affect post-treatment ovarian function by a reduction in ovarian reserve (i.e. the primordial follicle pool); a disturbed hormonal balance; or by anatomical or functional changes to the ovaries, uterus, cervix or vagina. Reduced ovarian function may result in infertility and premature ovarian insufficiency [POI; defined as oligo/amenorrhea for ≥4 months and follicle-stimulating hormone (FSH) levels of ≥25 IU/l on two occasions, 4 weeks apart, before the age of 40 years]. Notably, in cancer patients, menstrual function can resume many months after completion of treatment; in addition, infertility and POI may occur despite temporary resumption of menses. Ovarian reserve can be estimated by measuring serum anti-Müllerian hormone (AMH) levels (low levels represent low ovarian reserve) and/or antral follicle count. However, their clinical utility, particularly in predicting future fertility and reproductive lifespan, is unclear. ChT-related amenorrhea is mainly due to damage to growing follicles that occurs within weeks after ChT initiation and is often transient. Depending on age, pretreatment ovarian reserve and type of treatment, exhaustion of the primordial follicle pool may occur with subsequent POI. Because of their cell-cycle nonspecific mode of action, alkylating agents induce the greatest damage, not only to growing follicles but also to oocytes, resulting in a striking reduction of the primordial follicle pool.
The impact of most targeted agents (including monoclonal antibodies and small molecules) and immunotherapy is largely unknown. Limited data for the anti-human epidermal growth factor receptor 2 (HER2) agents trastuzumab and/or lapatinib indicate no apparent gonadotoxicity. An increased risk of ovarian dysfunction in patients treated with bevacizumab cannot be excluded.

Endocrine treatments may have an indirect effect on fertility by delaying time to pregnancy. A higher risk of treatment-related amenorrhoea with the use of tamoxifen following ChT has been described in several studies. Nonetheless, no impact on AMH levels has been shown. 

RT exposure causes a reduction in the number of ovarian follicles and has an adverse effect on uterine and endometrial function; the gonadotoxic effect of RT is dependent on the RT field, dose and fractionation schedule, with single doses more toxic than multiple fractions. RT-related ovarian follicle loss already occurs at doses of <2 Gy. The effective sterilising dose at which 97.5% of patients are expected to develop immediate POI decreases with increasing age at the time of treatment, ranging from 16 Gy at 20 years to 14 Gy at 30 years. RT also induces loss of uterine elasticity in a dose-dependent manner. This interferes with uterine distension, with increased risk throughout pregnancy.

A potential negative impact of cancer on ovarian reserve has been described for young women with lymphoma but not for patients with other malignancies.

**Recommendations**

- All cancer patients of reproductive age should receive complete oncofertility counselling as early as possible in the treatment planning process, irrespective of the type and stage of disease [III, A].
- Oncofertility counselling should be individualised based on patient/couple- and disease/treatment-related factors, with patient interest and age as well as type of treatment being the most important [V, A].
- Written information and/or online resources during oncofertility counselling should be provided to patients whenever possible [V, A].
- All patients with a potential interest in fertility preservation should be referred immediately to an appropriate fertility specialist/unit [III, A].
- As there is no absolute threshold of exposure to anticancer therapies that determines gonadal failure and infertility, every patient should be considered as being at potential risk of developing treatment-related gonadotoxicity [V, A].

**FERTILITY PRESERVATION: MALE PATIENTS**

A management flowchart for fertility preservation in male patients is shown in Figure 1.

**Sperm cryopreservation**

Sperm cryopreservation is a widely available and standard method to preserve an individual’s reproductive potential. This strategy relies on the survival and fertilisation capacity of spermatozoa after semen freezing, mostly in liquid nitrogen vapour or following controlled slow freezing. Since the introduction of intracytoplasmic sperm injection, freezing of a single semen sample containing mature sperm may be sufficient to attempt future fatherhood.

Success using cryopreserved sperm from cancer patients shows an aggregate rate for parenthood of 49% [95% confidence interval (CI) 44%-53%]. Long-term storage of cryopreserved sperm does not correlate with worse outcomes or thawed semen quality.

Sperm cryopreservation is indicated for adults and teenagers from Tanner pubertal stages II-III. If the patient is not able to ejaculate by masturbation, assisted ejaculation techniques such as penile vibratory stimulation or electroejaculation may be proposed. In case no sperm can be found in the semen sample, conventional testicular sperm extraction (TESE) or microsurgical TESE (microTESE) might be applied to extract sperm present in the testicular tissue. Sperm cryopreservation should be offered before treatment initiation because of potential genetic abnormalities in sperm after exposure to ChT or RT.

Data from longitudinal, prospective cohort studies are awaited to provide further evidence on the potential risk of congenital abnormalities.

**Gonadal shielding during RT**

Gonadal shielding during total-body RT protects the germinal epithelium. Adolescent (and childhood) patients who did not have testicular shielding had a significantly smaller testicular volume in adulthood compared with those who received testicular shielding. Diminished testosterone/luteinising hormone ratio was also reported without testicular shielding.

**Medical gonadoprotection**

Hormone suppression treatments such as a gonadotropin-releasing hormone agonist (GnRHa), with or without androgens, antiandrogens or progestins, are not protective in male cancer patients.

So far, other molecules have been tested in animals or in vitro, showing only partial effects, and none of them are in clinical use for this indication (supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2020.09.006).

**Other experimental options**

Information regarding other experimental options can be found in Section 1 of the supplementary Material, available at https://doi.org/10.1016/j.annonc.2020.09.006.

**Recommendations**

- Sperm cryopreservation before initiation of anticancer treatments (ChT, RT or surgery) is standard of care and should be discussed with any male cancer patient at risk of infertility [III, A].
To reduce the risk of infertility, reducing RT exposure by shielding or removing the testes from the radiation field should be applied whenever possible [IV, A].

Medical gonadoprotection (GnRHa with or without androgens, antiandrogens or progestins) should not be offered for fertility preservation in male cancer patients [III, D].

**Figure 1.** Management flowchart for fertility preservation in male patients.

microTESE, microsurgical testicular sperm extraction; TESE, testicular sperm extraction.
FERTILITY PRESERVATION: FEMALE PATIENTS

A management flowchart for ovarian function and/or fertility preservation in female patients is shown in Figure 2.

Oocyte and embryo cryopreservation

Oocytes and embryos can be safely and efficiently cryopreserved before the initiation of anticancer treatments. While embryo cryopreservation is an established and reproducible technology, it requires the use of sperm and the presence of a partner or donor. Conversely, oocyte cryopreservation can be carried out without a partner and so it is the preferred option for most post-pubertal women. The ability to cryopreserve oocytes has become much more successful in recent years since the development of ultra-rapid freezing (vitrification).34

For oocyte and embryo cryopreservation, ~2 weeks of ovarian stimulation with gonadotropins is required, followed by follicle aspiration. Ovarian stimulation can be started at any time of the menstrual cycle (‘random start stimulation’).35 Developments in ovarian stimulation protocols allow more rapid completion of the process than previously, without affecting their efficacy. However, timing is a crucial factor as the procedure must be completed before initiation of any ChT. In women with a low ovarian reserve and without an urgent need to initiate anticancer treatments, double stimulation can be considered; this requires 4 weeks of treatment and approximately doubles the number of oocytes retrieved.36

The efficacy of oocyte and embryo cryopreservation to generate a subsequent pregnancy is tightly connected to the number of mature oocytes retrieved after ovarian stimulation. The number of retrieved oocytes is reduced in women with poor ovarian reserve (i.e. low AMH level due to ovarian surgery or age). The number of collected oocytes is age dependent, varying from 15.4 ± 8.8 in women <26 years of age to 9.9 ± 8.0 in women 36-40 years of age.37 Recent data reported a cumulative live birth rate of 61.9% if 12 oocytes were cryopreserved in women ≤35 years of age and 43.4% if 10 oocytes were cryopreserved in women >35 years of age.38 While some studies have reported that the number of recovered oocytes in women with cancer is not reduced,37 others have found a reduction (particularly in lymphoma patients), with reduced fertilisation and implantation rates, resulting in a lower live birth rate compared with a noncancer population.38

Ovarian stimulation can lead to side-effects caused by the medication as well as complications during the oocyte pick-up, including bleeding from the ovary and pelvic infection. Severe ovarian hyperstimulation syndrome, clinically relevant bleeding or inflammation/infections after follicular aspiration in women with normal haematopoiesis are rare in the general infertility population and in cancer patients.39,40 An increased risk of bleeding or infection may be present in women with impaired haematopoiesis (i.e. neutropenic or with low platelet count), such as those with some haematological malignancies, and should be taken into account. In estrogen-sensitive tumours, reduction of estradiol concentration is recommended during ovarian stimulation and can be achieved by co-treatment with aromatase inhibitors (e.g. letrozole 2 × 2.5 mg/day), which reduces estrogen serum concentration by more than 50%.41 The use of letrozole does not reduce the number of mature oocytes obtained or their fertilisation capacity; in addition, no effect on congenital abnormality rates in children has been observed.62 Tamoxifen can also be used to antagonise the effects of high estrogen levels but data are less robust.43 Although numbers remain small, there is no evidence that ovarian stimulation for fertility preservation has an adverse effect on survival in women with breast cancer43 or other malignancies.44

It has been proposed that ovarian stimulation can be combined with cryopreservation of ovarian tissue to increase the success rate in women receiving highly gonadotoxic treatments.45 Half of an ovary is removed laparoscopically and ovarian stimulation is started 1-2 days later. Although data are very limited, the number of oocytes obtained does not appear to be significantly reduced after removal of ovarian tissue. The time required for the combination of both treatments is ~2.5 weeks.45

Oocyte or embryo cryopreservation is indicated for women preferably ≤40 years of age who will be exposed to gonadotoxic anticancer therapies and who want to preserve their fertility. It is not indicated in women with serious coagulation defects or high risk of infections. Transabdominal monitoring and oocyte recovery may be possible in those for whom vaginal procedures are not possible or acceptable. Women choosing to store embryos created with their partner’s sperm should be advised that the embryos will be the joint property of the couple; in the event of the relationship not continuing, there may be issues in using the embryos. An established collaboration between oncology and fertility units is crucial.

There is a need for data on all aspects of oocyte cryopreservation from larger series of women to clarify whether certain diagnoses may benefit from particular stimulation protocols, the effects on oocyte quality and most importantly, cumulative live birth rates. Future studies are also needed to investigate the benefits of combining different fertility-preservation methods to increase pregnancy rates.

Ovarian tissue cryopreservation

Ovarian tissue cryopreservation is an alternative approach for preserving fertility before gonadotoxic treatments.46,47 While it is still regarded as experimental in some countries, the American Society for Reproductive Medicine suggests that it should be considered as an established procedure to be offered to carefully selected patients.48

Biopsies of the ovarian cortex or unilateral ovariectomy are usually carried out by laparoscopy under general anaesthesia. No pretreatment is required so the process can be carried out in a short timeframe and ChT started the following day, if required. Although vitrification is quicker and less expensive,
slow freezing remains the standard of care because almost all pregnancies achieved after transplantation have been obtained using this procedure. Ovarian tissue cryopreservation should be offered only in laboratories with specific expertise and facilities to support safe tissue cryopreservation and storage for subsequent autologous transplantation, with necessary regulation. The ‘hub and spoke’ model, with ovarian surgery carried out locally and tissue transported to a central laboratory, may be preferred.

Transplantation, either orthotopic or heterotopic, is currently the only method available in clinical practice to restore ovarian function and fertility using cryopreserved ovarian tissue. More than 300 women worldwide have undergone the procedure and ovarian function restoration was achieved in 95% of cases within 4-9 months. To date, more than 180 babies have been born using this procedure. Approximately 85% of the women receiving ovarian transplants were cancer survivors. The live birth rate per patient...
was ~ 40%, half of which were from natural conceptions, thus avoiding the need for further medical intervention. As with oocyte and embryo cryopreservation, the main factor affecting success rate is age: women of younger age at ovarian tissue cryopreservation have better fertility outcomes after ovarian tissue transplantation than older women, with only a few pregnancies achieved in women over 36 years of age.50

Ovarian tissue collection and transplantation are usually carried out by laparoscopy. Surgical risk is considered low and complications (e.g. conversion laparotomy, bleeding, reintervention for cutaneous infection, bladder lesion or minor complications) are rare (0.2%-1.4%).51 The procedure should not be proposed to patients with high surgical/anaesthesia risks related to their disease and ideally should be done at the same time as other procedures that require anaesthesia. The risk of disease transmission during transplantation due to residual neoplastic cells within the ovarian cortex is one of the major safety concerns, especially in pelvic cancers or systemic diseases such as leukemia. Several diseases at advanced stages, such as Burkitt’s lymphoma, non-Hodgkin’s lymphoma, breast cancer and sarcoma, might also carry a risk of ovarian involvement.52 In a recent review, 9 out of 230 cancer patients who underwent ovarian tissue transplantation experienced recurrence of their disease but none were related to the transplantation procedure.49 Nevertheless, ovarian tissue should always be carefully analysed before grafting using all available technologies, such as immunohistoch­emistry and molecular markers, according to the disease. Xenografting has also been used in this context. Data on children are reassuring as no congenital malformations have been reported.

Ovarian tissue cryopreservation is appropriate when the time available before starting anticancer treatments is too short for ovarian stimulation and oocyte or embryo cryopreservation. Although there is no clear consensus on the maximum age for ovarian tissue cryopreservation, it is usually recommended to offer this procedure only to women ≤36 years of age.50,53 Ovarian tissue cryopreservation can also be carried out after an initial, low-intensity gonadotoxic treatment regimen in order to reduce the risk of neoplastic cells being present in the ovary (i.e. in leukemia patients) or when the patient’s initial health condition contraindicates an immediate procedure.54 Although the procedure has recently been carried out with success in a patient affected by acute myeloid leukaemia,55 the risk of tissue contamination remains a major concern in such patients and there is a need for very careful evaluation in each individual case. While normal oocytes can develop from cryopreserved ovarian tissue after ChT administration, there are no robust data regarding the impact of different regimens and time interval between last treatment dose and ovarian tissue cryopreservation on the subsequent reproductive outcomes. The ischaemic process after transplantation of ovarian cortex induces major follicular loss, reducing the lifespan of graft function. Restoration of ovarian function after grafting occurs in most women, but is very variable in duration, lasting from just a few months to several years in some cases. For some women, two or three graft procedures are required to achieve a pregnancy.59

Research is ongoing to improve tissue function after grafting using several tools, including human adipose tissue-derived stem cells, mesenchymal stem cells and decellularised scaffolds.

**Ovarian transposition and gonadal shielding during RT**

Two options exist for protecting ovaries from RT: trans­position of the ovaries before RT and gonadal shielding during RT.

Ovarian transposition outside the planned RT field is a routinely used technique to minimise ovarian follicle RT exposure. Although both laparotomic and laparoscopic approaches are possible, the procedure is mostly carried out by laparoscopy to accelerate recovery and avoid postponing RT.56 The ovary is mobilised with its vascular pedicle and the location is marked with radio-opaque clips to allow identification of the transposed ovary. It is possible to transpose only one ovary, but better results are achieved with a bilateral procedure. Transposition of the ovary into subc­utaneous tissue is another option but it is associated with a higher risk of cyst formation.56 Transposed ovaries can be safely punctured for oocyte retrieval.57 In certain cases, ovaries can be returned to their original location after RT. The rate of retained ovarian function is approximately 65% in patients undergoing surgery and RT.58 Reasons for failure include necrosis related to vascular impairment and migration after insufficient fixation. Success rate is influenced by the method of evaluation (presence of menstrual cycle, FSH levels, AMH levels) and the duration of follow-up (as ovarian function decreases over time). Very few data are available for pregnancy rates, which seem to vary between 0% and 50%, and these rates are also dependent on the target irradiated organ.56 The surgical risk of ovarian transposition is similar to other gynaecological procedures (i.e. risk of bowel and vessel injury). Risk of developing ovarian carcinoma in a transposed ovary is extremely low.56 This could be reduced even further when fallopian tubes are resected during the surgical procedure.

Gonadal shielding during RT by lead blocks reduces the expected RT dose to 4-5 Gy.59 The minimum free margin should be 2 cm in order to reduce the risk of gonadal irradiation due to inner organ movement.

Ovarian transposition and gonadal shielding are indicated in women ≤40 years of age who are scheduled to receive pelvic RT for cervical (if there is a low risk of ovarian metastasis or recurrence), vaginal, rectal or anal cancers, Hodgkin’s or non-Hodgkin’s lymphoma in the pelvis or Ewing’s sarcoma of the pelvis.

Long-term follow-up evaluating the risks of transposition and fertility rates after RT completion is needed.

**Medical gonadoprotection**

The aim of medical gonadoprotection during ChT is to reduce the risk of POI and its associated fertility and endocrine-related consequences. Therefore, this strategy
may also be of value in patients without a desire for pregnancy and not interested in fertility preservation. Potential advantages are its suitability for premenopausal patients of all ages, non-invasive nature, low health risk and possible use in conjunction with fertility-preservation strategies. The potential disadvantages of medical gonadoprotection are the possible interference with anticancer therapies, risk of damaging the oocytes and the need for administering these agents before and during anticancer treatment.

Temporary ovarian suppression during ChT achieved by administering a GnRHa (starting at least 1 week before the initiation of systemic cytotoxic therapy and continued for the duration of therapy) is the only strategy that has entered clinical use. Several potential new methods of medical gonadoprotection with hormonal and non-hormonal agents are currently under investigation (supplementary Table S2, available at https://doi.org/10.1016/j.annonc.2020.09.006).

In cancer patients, most of the available randomised trials assessing the use of GnRHAs during ChT have been conducted in premenopausal breast cancer patients, but evidence also exists in women with haematological malignancies; there are limited data to counsel cancer patients diagnosed with other solid tumours. Notably, in most of the trials, the primary end point was POI (defined as amenorrhea at different time points following ChT completion, with few trials using composite end points of amenorrhea and postmenopausal hormonal levels). A small number of studies reported on post-treatment pregnancies.

In premenopausal breast cancer patients, 14 randomised trials investigated the efficacy of this strategy: all but four studies showed a statistically significant reduction in POI risk with concurrent administration of a GnRHa during systemic cytotoxic therapy. In an individual patient-level meta-analysis including the five major breast cancer trials (N = 873), the administration of a GnRHa during ChT was associated with a significant reduction in POI rates [from 30.9% to 14.1%; adjusted odds ratio (OR) 0.38; 95% CI 0.26-0.57; \( P < 0.001 \)] and a higher number of post-treatment pregnancies [37 versus 20; incidence rate ratio (IRR) 1.83; 95% CI 1.06-3.15]. Treatment effect in reducing POI risk was observed in both patients with hormone receptor-positive and -negative disease and was irrespective of patient age at the time of treatment, type and duration of ChT.

In premenopausal women with haematological malignancies, four randomised trials investigated the efficacy of this strategy but none showed a protective effect with the use of a GnRHa during ChT. A recent meta-analysis included three trials (N = 109 patients) and showed no significant difference in POI rates [18.9% versus 32.1%; risk ratio (RR) 0.70; 95% CI 0.20-2.47] or post-treatment pregnancies (17 versus 18; RR 1.13; 95% CI 0.66-1.93) between patients that received ChT alone and those with concurrent GnRHa administration.

In premenopausal women with other solid tumours, only one randomised trial including 30 patients with ovarian cancer is available. A significant reduction in POI rates (from 33.3% to 0.0%; \( P = 0.02 \)) was observed with the use of a GnRHa during ChT; no data on post-treatment pregnancies were reported.

In terms of safety, concurrent use of a GnRHa during ChT is associated with a higher incidence of menopausal symptoms (mainly hot flushes and sweating) that are of low severity grade in the majority of cases and are reversible. In women with hormone receptor-positive breast cancer, concurrent administration of a GnRHa during ChT is not associated with detrimental survival outcomes; subsequent ovarian function suppression should be considered as part of the adjuvant endocrine treatment in these patients.

Based on the available evidence, temporary ovarian suppression with a GnRHa during ChT should be considered a standard option for ovarian function preservation in premenopausal breast cancer patients undergoing (neo)adjuvant systemic cytotoxic therapy. In premenopausal women with other malignancies who are candidates to receive ChT, despite the limited available data, use of a GnRHa may be discussed considering its other potential medical effects, including menstrual cycle control and prevention of menometrorrhagia risk. Importantly, for patients interested in fertility preservation, temporary ovarian suppression with a GnRHa during ChT should not be considered as an alternative to cryopreservation techniques. In this setting, a GnRHa can be offered but only following cryopreservation procedures or when these surgical options are not accessible (for logistical, timing, cost or personal ethical reasons).

Further research efforts are needed to collect long-term follow-up data (including post-treatment pregnancies and age at menopause) from existing randomised trials. Prospective studies are warranted to better investigate the protective gonadal effect of a GnRHa during ChT using more sensitive markers of ovarian reserve, including AMH levels and antral follicle count.

Other experimental options

Information regarding other experimental options for female fertility preservation can be found in Section 2 of the supplementary Material, available at https://doi.org/10.1016/j.annonc.2020.09.006.

**Recommendations**

- When a 2-week treatment delay is feasible, oocytes or embryos can be safely and efficiently cryopreserved before the initiation of anticancer therapies [III, A].
- Close links with reproductive medicine centres are required to allow timely referral for counselling and access to oocyte and embryo cryopreservation [V, A].
- Random start ovarian stimulation protocols should be applied to limit the delay in starting anticancer treatments [III, A].
- As age is a major determinant of the likelihood of success, women should be clearly advised of their age-related chance of achieving a successful pregnancy [III, A].
• Aromatase inhibitors can be given to prevent supraphysiologlcal estrogen concentrations during ovarian stimulation in women with estrogen-sensitive tumours [III, C].
• Ovarian tissue cryopreservation is an alternative procedure when oocyte or embryo cryopreservation are not feasible [III, A] with the following considerations:
  ○ Ovarian tissue cryopreservation should not be offered to older women: current evidence supports 36 years as an age limit [III, B].
  ○ Fragments of ovarian tissue (medulla and/or cortex) should always be analysed for the presence of neoplastic cells with appropriate techniques before transplantation [III, A]. Transplantation should be considered with particular caution in cases of acute leukaemia, or any solid tumour or haematological disease with pelvic involvement [III, A].
  ○ Ovarian tissue cryopreservation can be carried out after exposure to induction or a few low-intensity gonadotoxic ChT cycles [IV, B]. This approach might be of interest in patients with systemic diseases, such as leukaemia, to reduce the risk of transplanting residual malignant cells that were within the ovary before cryopreservation [V, C].
• Ovarian transposition should be considered in order to try to preserve ovarian function in women ≤40 years of age with an indication for pelvic RT [IV, A].
• Ovarian transposition should be carried out by experienced laparoscopists to minimise complications and maximise the chances of ovarian function preservation [IV, A].
• Gonadal shielding may be an alternative strategy to ovarian transposition, not requiring a surgical intervention [IV, C].
• For premenopausal breast cancer patients undergoing (neo)adjuvant ChT, temporary ovarian suppression with a GnRHa is recommended for ovarian function preservation, irrespective of tumour subtype [I, A].
• For premenopausal women with malignancies other than breast cancer, temporary ovarian suppression with a GnRHa during ChT may be considered as an option to potentially reduce POI risk and menometrorrhagia, but the limited and controversial evidence should be discussed with the patient [II, C].
• For young cancer patients interested in fertility preservation, temporary ovarian suppression with a GnRHa during ChT should not be considered as an alternative to oocyte or embryo cryopreservation, but it may be offered as an additional option following cryopreservation strategies or when they are not accessible [V, C].

**POST-TREATMENT PREGNANCIES IN CANCER SURVIVORS**

At the time of diagnosis, a significant proportion of post-pubertal patients have not completed their family planning and express a desire for pregnancy after treatment. Nevertheless, male and female cancer survivors have significantly reduced chances of post-treatment pregnancies compared with the general population. Post-treatment pregnancy rates are highly dependent on the type of cancer, with the lowest rates reported for men with a history of acute leukaemia or non-Hodgkin’s lymphoma and for women with a history of breast or cervical cancer.

When counselling adult cancer survivors inquiring into the feasibility and safety of post-treatment pregnancies, both patient/couple- and disease/treatment-related factors should be taken into consideration (Table 4). The potential negative influence of prior exposure to anticancer treatments on the occurrence of congenital abnormalities or obstetric and birth complications, and the possibility that a pregnancy might have a detrimental prognostic effect for the patient, particularly in the case of hormone-driven tumours, are two major concerns shared by both adult cancer survivors and their treating physicians.

While no difference has been shown for female partners of male cancer survivors, there is an increased risk of developing obstetric and birth complications for female cancer survivors in terms of increased risk of prematurity (RR 1.56; 95% CI 1.37–1.77), low birth weight (RR 1.47; 95% CI 1.24–1.73), elective (RR 1.38; 95% CI 1.13–1.70) and emergency caesarean section (RR 1.22; 95% CI 1.15–1.30), assisted vaginal delivery (RR 1.10; 95% CI 1.02–1.18) and postpartum haemorrhage (RR 1.18; 95% CI 1.02–1.36). The risk of these complications appears to be higher when the interval between the end of treatment and conception is short. Therefore, close monitoring of post-treatment pregnancies and an interval of at least 1 year following completion of ChT is recommended in cancer survivors. In patients receiving other anticancer treatments, a specific wash-out period should be considered before conception (e.g. 3 months for tamoxifen and 7 months for the anti-HER2 monoclonal antibody trastuzumab).

Neonatal outcomes of pregnancies in men or women with prior exposure to anticancer treatments appear to be comparable to those of the general population. Although the literature is controversial and relies on register-based studies, a slightly increased risk of congenital

**Table 4. Patient/couple- and disease/treatment-related factors to be considered during the counselling of post-pubertal cancer survivors inquiring into the feasibility and safety of post-treatment pregnancies**

<table>
<thead>
<tr>
<th>Patient/couple-related factors</th>
<th>Disease/treatment-related factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Type of cancer (prognosis and biology)</td>
</tr>
<tr>
<td>Age</td>
<td>Type, dose and duration of prior treatment (ChT, RT, endocrine therapy, surgery)</td>
</tr>
<tr>
<td>Personal status</td>
<td>Interval since treatment completion</td>
</tr>
<tr>
<td>BMI</td>
<td>Need for additional treatment</td>
</tr>
<tr>
<td>Smoking</td>
<td>Potential risk associated with treatment interruption</td>
</tr>
<tr>
<td>Presence of a partner</td>
<td>Previous treatment for infertility</td>
</tr>
<tr>
<td>Medical history</td>
<td>Prior treatment with potential negative impact on fertility</td>
</tr>
<tr>
<td>Previous treatment for infertility</td>
<td>Prior access to fertility-preservation options</td>
</tr>
<tr>
<td>Hereditary conditions</td>
<td>Contraindications to pregnancy</td>
</tr>
</tbody>
</table>

BMI, body mass index; ChT, chemotherapy; RT, radiotherapy.
abnormalities has been reported in offspring of male cancer survivors (3.7% versus 3.2%; RR 1.17; 95% CI 1.05-1.31) when either cryopreserved sperm or fresh post-treatment sperm was used. A slightly increased risk of congenital anomalies has also been described in female patients (RR 1.10; 95% CI 1.02-1.20) but this was interpreted as an artefact of the analysis.

A growing amount of data (derived mostly from retrospective studies) supports the safety of conceiving following adequate treatment and follow-up of patients with breast cancer, including those with prior estrogen receptor-positive disease. Abortion, time to pregnancy and breastfeeding do not appear to have any impact on patient outcomes. In young women with a history of hormone receptor-positive breast cancer who are candidates for 5-10 years of adjuvant endocrine therapy, no reliable data are available to counsel women on the safety of a temporary treatment interruption to have a pregnancy. In women who consider this option, patient wishes (and partner, if appropriate), age, availability of cryopreserved gametes and individual risk of recurrence are of paramount importance to be discussed. Following delivery, adjuvant endocrine therapy should be resumed to complete the recommended 5-10 years of treatment. The international, multicentre, prospective POSITIVE trial (ClinicalTrial.gov: NCT02308085) will shed light on the safety of a temporary treatment interruption to have a pregnancy in patients with prior estrogen receptor-positive disease.

The feasibility and safety of using assisted reproductive technology (ART) following anticancer treatment is an important issue to be considered for adult cancer survivors who did not have access to fertility preservation strategies at the time of diagnosis and/or where there are difficulties with spontaneous conception. Female adult cancer survivors have a higher likelihood of undergoing fertility treatments compared with healthy women, with increasing use over time. In terms of efficacy, significantly lower live birth rates with the use of autologous oocytes were described for cancer survivors compared with healthy women (24.7% versus 47.7%). A major impact of cancer type was shown, with the lowest live birth rates observed among breast cancer patients (14.3%) and the highest in those with a prior history of melanoma (53.5%). Conversely, in women using donor oocytes, no significant difference was observed in live birth rates between cancer survivors and healthy women (60.4% versus 64.5%), irrespective of cancer type. These results further reinforce the recommendation to refer patients interested in pursuing fertility preservation strategies before the initiation of anticancer treatment. In women with hormone-driven cancers, such as survivors of hormone receptor-positive breast cancer, an additional concern is the potential detrimental effect of ART on survival outcomes. While the available safety data are reassuring for ART at the time of diagnosis when followed by the use of systemic anticancer therapies, data are limited to counsel breast cancer survivors about the safety of using ART during oncological follow-up, particularly when ovarian stimulation is needed. Although there is no apparent detrimental prognostic effect, evidence is limited to draw solid conclusions in this setting and more research is needed.

**Recommendations**

- Patient/couple- and disease/treatment-related factors should be considered when counselling adult cancer survivors regarding the feasibility and safety of post-treatment pregnancies [V, A].
- After adequate treatment and follow-up, having a pregnancy in cancer survivors should not be discouraged for safety reasons, even among women with a prior history of hormone receptor-positive breast cancer [IV, B].
- Post-treatment pregnancies in adult women with a prior history of cancer should be monitored more closely due to the potential increased risk of developing obstetric and birth complications [IV, B].
- Breastfeeding can be considered in cancer survivors who are not under active treatment [IV, B].
- Fertility preservation strategies should preferably be used at the time of diagnosis before treatment initiation [III, A].
- Where appropriate and allowed by local regulations, oocyte donation can be considered as an option in cancer survivors [IV, C].

**FERTILITY AND POST-TREATMENT PREGNANCIES IN POST-PUBERTAL PATIENTS WITH HEREDITARY CANCER SYNDROMES**

Hereditary cancer syndromes are often associated with a significantly increased risk of developing early onset cancer. Several hereditary cancer syndromes are characterised by an increased chance of gynaecological cancers, including ovarian and endometrial neoplasms (supplementary Table S3, available at https://doi.org/10.1016/j.annonc.2020.09.006). The identification of an inherited deleterious pathogenic variant in one of these genes plays a significant role both in cancer management and in screening, prevention and risk-reducing measures, with the subsequent impact on the patient’s reproductive potential. As testing becomes more widespread, including the use of multigene panels, increased attention to fertility and pregnancy-related issues in post-pubertal patients with hereditary cancer syndromes is necessary. For some of these syndromes, the recommendation to pursue risk-reducing gynaecological surgery at a young age leads to a particularly narrow window for fertility and pregnancy. As recommended by current guidelines, all women harbouring a predisposing pathogenic variant should be encouraged to complete childbearing before planned risk-reducing gynaecological surgery. At present, the recommended risk-reducing measure for women at increased risk of ovarian cancer is bilateral salpingo-oophorectomy. Of note, there is an increasing body of evidence suggesting that epithelial ovarian cancers originate in the fimbria or fallopian tubes. Although risk-reducing salpingectomy alone cannot be
recommended at present outside of a clinical trial, if data emerge to support the safety of this approach, this will favourably impact reproductive issues and fertility options for these patients.

Preclinical data suggest a potential negative impact of harvesting a germline pathogenic variant in genes involved in DNA repair mechanisms on female fertility in terms of decreasing ovarian reserve, increasing fertility-related issues and POI that can lead to infertility and premature menopause. Controversial data have been reported on the potential tendency for reduced ovarian reserve at diagnosis and before commencement of anticancer treatments in \( BRCA \)-mutated breast cancer patients. To date, the potential concerns about an increased risk of gonadotoxicity in patients with hereditary cancer syndromes have not been supported by the (albeit limited) available evidence. Clinical data on how to optimally counsel patients with hereditary cancer syndromes facing fertility and pregnancy-related concerns remain limited. Overall, similar recommendations on fertility preservation and post-treatment pregnancies for women without germline predisposing pathogenic variants apply to patients with hereditary cancer syndromes, including the need for appropriate oncofertility counselling at the time of diagnosis. However, specific considerations should be made regarding fertility preservation, particularly for women with predisposing pathogenic variants associated with an increased risk of ovarian cancer.

Sperm cryopreservation in men and oocyte or embryo cryopreservation in women are the preferred options to be offered to newly diagnosed patients with hereditary cancer syndromes interested in fertility preservation. Importantly, these techniques facilitate the use of preimplantation genetic diagnosis (PGD) for patients who are interested in this option. Controversial data have been reported on the tendency towards a reduced response to controlled ovarian stimulation in \( BRCA \)-mutated breast cancer patients.

In women with hereditary cancer syndromes that are associated with an increased risk of gynaecological malignancy and who are candidates for risk-reducing gynaecological surgery, ovarian tissue cryopreservation and temporary ovarian suppression with a GnRHa during ChT may be considered as supplementary measures to oocyte or embryo cryopreservation. Of note, a genetic test result is often not available for patients at the time of diagnosis and during oncofertility counselling, but it should be known before transplantation of cryopreserved tissue. There are limited data available to counsel patients with hereditary cancer syndromes on the efficacy and safety of these approaches with one concern being transplanting ovarian tissue that may harbour premalignant changes. Acknowledging the limited evidence in this regard, for patients with hereditary cancer syndromes, the choice of the transplantation site, such as directly into the remaining gonads, is crucial to ensure that all ovarian tissue can be removed after the completion of reproductive plans at the time of risk-reducing gynaecological surgery.

Available data suggest that post-treatment pregnancies are feasible among \( BRCA \)-mutated breast cancer patients, with no detrimental prognostic effect and no increased risk of congenital abnormalities or obstetric or birth complications. Although there is a lack of evidence for patients with pathogenic variants other than \( BRCA \), there are no plausible reasons to anticipate different safety considerations for post-treatment pregnancies between cancer survivors with or without hereditary cancer syndromes.

An important concern among patients with a hereditary cancer syndrome is the 50% risk of transmitting the mutated gene to their children. Patients (both male and female) with a hereditary cancer syndrome, particularly those harbouring a high penetrance pathogenic variant, planning to conceive should be made aware of the options of prenatal diagnosis (via chorionic-villous or amniotic fluid sampling in week 11-20 of gestation) and PGD. The risks and benefits of both approaches need to be carefully outlined, and the need for in vitro fertilisation (IVF), irrespective of fertility status, if PGD is chosen must be clearly stated. A multitude of factors, including religious, cultural, ethical and socioeconomic factors can influence an individual’s choice to utilise prenatal diagnosis or PGD, and any decisions should be respected. An increased awareness is needed to ensure adequate discussions on this topic, with interested patients referred to relevant experts and centres. It is worth noting, however, that these technologies are not available in all countries/centres.

Further research efforts to improve our understanding of the role of predisposing genes on patients’ reproductive potential and subsequent risk of treatment-related gonadotoxicity, as well as to investigate the efficacy and safety of fertility-preservation strategies in patients with hereditary cancer syndromes, should be considered a research priority.

\textbf{Recommendations}

- Sperm cryopreservation and oocyte or embryo cryopreservation are the preferred options and should be proposed to newly diagnosed patients with hereditary cancer syndromes interested in fertility preservation [IV, A].
- Ovarian tissue cryopreservation and temporary ovarian suppression with a GnRHa during ChT may be considered as supplementary measures to oocyte or embryo cryopreservation. Of note, a genetic test result is often not available for patients at the time of diagnosis and during oncofertility counselling, but it should be known before transplantation of cryopreserved tissue. There are limited data available to counsel patients with hereditary cancer syndromes on the efficacy and safety of these approaches with one concern being transplanting ovarian tissue that may harbour premalignant changes. Acknowledging the limited evidence in this regard, for patients with hereditary cancer syndromes, the choice of the transplantation site, such as directly into the remaining gonads, is crucial to ensure that all ovarian tissue can be removed after the completion of reproductive plans at the time of risk-reducing gynaecological surgery.
- Post-treatment pregnancies in \( BRCA \)-mutated breast cancer survivors should not be discouraged [IV, B]. Although no data are available for patients with pathogenic variants other than \( BRCA \), there are no plausible reasons to anticipate different safety considerations for post-treatment pregnancies between cancer survivors with or without hereditary cancer syndromes [V, B].
- Patients with hereditary cancer syndromes should be informed of the possibility to undergo prenatal diagnosis (in the case of natural conception) or PGD (in the case of IVF procedures) [III, A].
METHODOLOGY

These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development (https://www.esmo.org/guidelines/esmo-guidelines-methodology). The relevant literature has been selected by the expert authors. Levels of evidence and grades of recommendation have been applied using the system shown in supplementary Table S4, available at https://doi.org/10.1016/j.anonc.2020.09.006. Statements without grading were considered justifiable standard clinical practice by the experts.

ACKNOWLEDGEMENTS

ML acknowledges the support of ESMO for a Translational Research Fellowship in the field of oncofertility during his PhD at the Université Libre de Bruxelles (ULB) in Brussels, Belgium. Manuscript editing support was provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO.

FUNDING

No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds.

DISCLOSURE

ML reported consultancy or advisory role and speaker’s honoraria from Roche, Theramex, Takeda, Pfizer, Novartis and Lilly; FAP reported consultancy or advisory role and speaker’s honoraria from Roche, Clovis, Takeda and Ipsen; ID reported advisory role and speaker’s honoraria from Roche and Novartis; FA is a senior researcher for the Research Fund Flanders (FWO); SPS reported consultancy or advisory role and speaker’s honoraria from Roche, Novartis, Pfizer and AstraZeneca. RAA reported consultancy and research support from Roche Diagnostics, Ferrin Pharmaceuticals, IBSA and Merck; KJ reported speaker honoraria from Roche, Novartis, Pfizer and AstraZeneca.

The remaining authors have declared no potential conflicts of interest.

REFERENCES

M. Lambertini et al.


